INTRODUCTION: Podoplanin/aggrus is a mucin-like sialoglycoprotein that is highly expressed in malignant gliomas. Podoplanin has been reported to be a novel marker to enrich tumor-initiating cells, which are thought to resist conventional therapies and to be responsible for cancer relapse. The purpose of this study was to determine whether an anti-podoplanin antibody is suitable to target radionuclides to malignant gliomas. METHODS: The binding affinity of an anti-podoplanin antibody, NZ-1 (rat IgG(2a)), was determined by surface plasmon resonance and Scatchard analysis. NZ-1 was radioiodinated with (125)I using Iodogen [(125)I-NZ-1(Iodogen)] or N-succinimidyl 4-guanidinomethyl 3-[(131)I]iodobenzoate ([(131)I]SGMIB-NZ-1), and paired-label internalization assays of NZ-1 were performed. The tissue distribution of (125)I-NZ-1(Iodogen) and that of [(131)I]SGMIB-NZ-1 were then compared in athymic mice bearing glioblastoma xenografts. RESULTS: The dissociation constant (K(D)) of NZ-1 was determined to be 1.2 × 10(-10) M by surface plasmon resonance and 9.8 × 10(-10) M for D397MG glioblastoma cells by Scatchard analysis. Paired-label internalization assays in LN319 glioblastoma cells indicated that [(131)I]SGMIB-NZ-1 resulted in higher intracellular retention of radioactivity (26.3 ± 0.8% of initially bound radioactivity at 8 h) compared to that from the (125)I-NZ-1(Iodogen) (10.0 ± 0.1% of initially bound radioactivity at 8 h). Likewise, tumor uptake of [(131)I]SGMIB-NZ-1 (39.9 ± 8.8 %ID/g at 24 h) in athymic mice bearing D2159MG xenografts in vivo was significantly higher than that of (125)I-NZ-1(Iodogen) (29.7 ± 6.1 %ID/g at 24 h). CONCLUSIONS: The overall results suggest that an anti-podoplanin antibody NZ-1 warrants further evaluation for antibody-based therapy against glioblastoma.
INTRODUCTION:Podoplanin/aggrus is a mucin-like sialoglycoprotein that is highly expressed in malignant gliomas. Podoplanin has been reported to be a novel marker to enrich tumor-initiating cells, which are thought to resist conventional therapies and to be responsible for cancer relapse. The purpose of this study was to determine whether an anti-podoplanin antibody is suitable to target radionuclides to malignant gliomas. METHODS: The binding affinity of an anti-podoplanin antibody, NZ-1 (rat IgG(2a)), was determined by surface plasmon resonance and Scatchard analysis. NZ-1 was radioiodinated with (125)I using Iodogen [(125)I-NZ-1(Iodogen)] or N-succinimidyl 4-guanidinomethyl 3-[(131)I]iodobenzoate ([(131)I]SGMIB-NZ-1), and paired-label internalization assays of NZ-1 were performed. The tissue distribution of (125)I-NZ-1(Iodogen) and that of [(131)I]SGMIB-NZ-1 were then compared in athymic mice bearing glioblastoma xenografts. RESULTS: The dissociation constant (K(D)) of NZ-1 was determined to be 1.2 × 10(-10) M by surface plasmon resonance and 9.8 × 10(-10) M for D397MG glioblastoma cells by Scatchard analysis. Paired-label internalization assays in LN319 glioblastoma cells indicated that [(131)I]SGMIB-NZ-1 resulted in higher intracellular retention of radioactivity (26.3 ± 0.8% of initially bound radioactivity at 8 h) compared to that from the (125)I-NZ-1(Iodogen) (10.0 ± 0.1% of initially bound radioactivity at 8 h). Likewise, tumor uptake of [(131)I]SGMIB-NZ-1 (39.9 ± 8.8 %ID/g at 24 h) in athymic mice bearing D2159MG xenografts in vivo was significantly higher than that of (125)I-NZ-1(Iodogen) (29.7 ± 6.1 %ID/g at 24 h). CONCLUSIONS: The overall results suggest that an anti-podoplanin antibody NZ-1 warrants further evaluation for antibody-based therapy against glioblastoma.
Authors: Ester Martín-Villar; Francisco G Scholl; Carlos Gamallo; Maria M Yurrita; Mario Muñoz-Guerra; Jesús Cruces; Miguel Quintanilla Journal: Int J Cancer Date: 2005-03-01 Impact factor: 7.396
Authors: Kimberly L Dumoff; Christina S Chu; Eleanor E Harris; David Holtz; Xiaowei Xu; Paul J Zhang; Geza Acs Journal: Mod Pathol Date: 2006-05 Impact factor: 7.842
Authors: C J Reist; G E Archer; S N Kurpad; C J Wikstrand; G Vaidyanathan; M C Willingham; D K Moscatello; A J Wong; D D Bigner; M R Zalutsky Journal: Cancer Res Date: 1995-10-01 Impact factor: 12.701
Authors: T Saga; R D Neumann; T Heya; J Sato; S Kinuya; N Le; C H Paik; J N Weinstein Journal: Proc Natl Acad Sci U S A Date: 1995-09-12 Impact factor: 11.205
Authors: Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks Journal: Nature Date: 2004-11-18 Impact factor: 49.962
Authors: Harini Krishnan; Edward P Retzbach; Maria I Ramirez; Tong Liu; Hong Li; W Todd Miller; Gary S Goldberg Journal: Exp Cell Res Date: 2015-05-07 Impact factor: 3.905
Authors: Harini Krishnan; Jhon A Ochoa-Alvarez; Yongquan Shen; Evan Nevel; Meenakshi Lakshminarayanan; Mary C Williams; Maria I Ramirez; W Todd Miller; Gary S Goldberg Journal: J Biol Chem Date: 2013-03-25 Impact factor: 5.157
Authors: G Vaidyanathan; B J White; D J Affleck; X G Zhao; P C Welsh; D McDougald; J Choi; M R Zalutsky Journal: Bioorg Med Chem Date: 2012-10-29 Impact factor: 3.641
Authors: Hui K Gan; Martin van den Bent; Andrew B Lassman; David A Reardon; Andrew M Scott Journal: Nat Rev Clin Oncol Date: 2017-07-04 Impact factor: 66.675
Authors: Jhon Alberto Ochoa-Alvarez; Harini Krishnan; Yongquan Shen; Nimish K Acharya; Min Han; Dean E McNulty; Hitoki Hasegawa; Toshinori Hyodo; Takeshi Senga; Jian-Guo Geng; Mary Kosciuk; Seung S Shin; James S Goydos; Dmitry Temiakov; Robert G Nagele; Gary S Goldberg Journal: PLoS One Date: 2012-07-23 Impact factor: 3.240
Authors: Vidyalakshmi Chandramohan; Xuhui Bao; Mika Kato Kaneko; Yukinari Kato; Stephen T Keir; Scott E Szafranski; Chien-Tsun Kuan; Ira H Pastan; Darell D Bigner Journal: Int J Cancer Date: 2012-11-23 Impact factor: 7.316